Maria Lage Barca1, Karin Persson2, Rannveig Eldholm3, Jūratė Šaltytė Benth4, Hege Kersten5, Anne-Brita Knapskog6, Ingvild Saltvedt7, Geir Selbaek8, Knut Engedal2. 1. Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Norway; Department of Geriatric Medicine, Oslo University Hospital, Norway. Electronic address: maria.barca@aldringoghelse.no. 2. Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Norway; Department of Geriatric Medicine, Oslo University Hospital, Norway. 3. Department of Neuromedicine and Movement science, NTNU, Norwegian University of Science and Technology, Trondheim, Norway. 4. Institute of Clinical Medicine, Campus Ahus, University of Oslo, Norway; HØKH, Research Centre, Akershus University Hospital, Norway. 5. Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Norway; Department of Pharmaceutical Bioscience, School of Pharmacy, University of Oslo, Norway; Telemark Hospital Trust, Skien, Norway. 6. Department of Geriatric Medicine, Oslo University Hospital, Norway. 7. Department of Neuromedicine and Movement science, NTNU, Norwegian University of Science and Technology, Trondheim, Norway; Geriatric Department, St. Olav Hospital, University Hospital of Trondheim, Norway. 8. Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Norway; Research Centre for Old Age Psychiatric Research, Innlandet Hospital Trust, Ottestad, Norway.
Abstract
BACKGROUND: The relationship between progression of Alzheimer's disease and depression and its underlying mechanisms has scarcely been studied. METHODS: A sample of 282 outpatients with Alzheimer's disease (AD; 105 with amnestic AD and 177 with Alzheimer's dementia) from Norway were followed up for an average of two years. Assessment included Cornell Scale for Depression in Dementia and Clinical Dementia Rating Scale (CDR) at baseline and follow-up to examine the relationship between AD and depression. Additionally, MRI of the brain, CSF dementia biomarkers and APOE status were assessed at baseline. Progression of dementia was defined as the difference between CDR sum of boxes at follow-up and baseline (CDR-SB change). Trajectories of depressive symptoms on the Cornell Scale were identified using growth mixture modeling. Differences between the trajectories in regard to patients' characteristics were investigated. RESULTS: Three distinct trajectories of depressive symptoms were identified: 231 (82.8%) of the patients had stable low-average scores on the Cornell Scale (Class 1); 11 (3.9%) had high and decreasing scores (Class 2); and 37 (13.3%) had moderate and increasing scores (Class 3). All classes had average probabilities over 80%, and confidence intervals were non-overlapping. The only significant characteristic associated with membership in class 3 was CDR-SB change. LIMITATIONS: Not all patients screened for participation were included in the study, but the included and non-included patients did not differ significantly. Some patients with amnestic MCI might have been misdiagnosed. CONCLUSION: A more rapid progression of dementia was found in a group of patients with increasing depressive symptoms.
BACKGROUND: The relationship between progression of Alzheimer's disease and depression and its underlying mechanisms has scarcely been studied. METHODS: A sample of 282 outpatients with Alzheimer's disease (AD; 105 with amnestic AD and 177 with Alzheimer's dementia) from Norway were followed up for an average of two years. Assessment included Cornell Scale for Depression in Dementia and Clinical Dementia Rating Scale (CDR) at baseline and follow-up to examine the relationship between AD and depression. Additionally, MRI of the brain, CSF dementia biomarkers and APOE status were assessed at baseline. Progression of dementia was defined as the difference between CDR sum of boxes at follow-up and baseline (CDR-SB change). Trajectories of depressive symptoms on the Cornell Scale were identified using growth mixture modeling. Differences between the trajectories in regard to patients' characteristics were investigated. RESULTS: Three distinct trajectories of depressive symptoms were identified: 231 (82.8%) of the patients had stable low-average scores on the Cornell Scale (Class 1); 11 (3.9%) had high and decreasing scores (Class 2); and 37 (13.3%) had moderate and increasing scores (Class 3). All classes had average probabilities over 80%, and confidence intervals were non-overlapping. The only significant characteristic associated with membership in class 3 was CDR-SB change. LIMITATIONS: Not all patients screened for participation were included in the study, but the included and non-included patients did not differ significantly. Some patients with amnestic MCI might have been misdiagnosed. CONCLUSION: A more rapid progression of dementia was found in a group of patients with increasing depressive symptoms.
Authors: Maria Lage Barca; Dag Alnæs; Knut Engedal; Karin Persson; Rannveig Sakshaug Eldholm; Nikias Siafarikas; Ina Selseth Almdahl; Maria Stylianou-Korsnes; Ingvild Saltvedt; Geir Selbæk; Lars T Westlye Journal: Dement Geriatr Cogn Dis Extra Date: 2022-06-23
Authors: Luis Agüera-Ortiz; Rocío García-Ramos; Francisco J Grandas Pérez; Jorge López-Álvarez; José Manuel Montes Rodríguez; F Javier Olazarán Rodríguez; Javier Olivera Pueyo; Carmelo Pelegrin Valero; Jesús Porta-Etessam Journal: Front Psychiatry Date: 2021-02-26 Impact factor: 4.157
Authors: Leonie C P Banning; Inez H G B Ramakers; Paul B Rosenberg; Constantine G Lyketsos; Jeannie-Marie S Leoutsakos Journal: Int J Geriatr Psychiatry Date: 2020-09-11 Impact factor: 3.485
Authors: Shawn M McClintock; Lex Minto; David A Denney; K Chase Bailey; C Munro Cullum; Vonetta M Dotson Journal: Curr Psychiatry Rep Date: 2021-07-13 Impact factor: 8.081